GSK’s Investigational Liver Therapy, Efimosfermin, Receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) Designations for MASH
Summary
GSK plc (LSE NYSE GSK) today announced that efimosfermin, a once-monthly investigational liver therapy, has been granted Breakthrough Therapy Designation by the
Description
GSK plc (LSE NYSE GSK) today announced that efimosfermin, a once-monthly investigational liver therapy, has been granted Breakthrough Therapy Designation by the
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source